Monitor the pace of ATM sales and any further dilutive filings. The company's going concern status and heavy reliance on equity financing suggest continued stock price pressure. Watch for the next 10-Q to assess cash burn and any guidance on achieving profitability.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
bioAffinity Technologies filed a 424B5 prospectus supplement to correct a typographical error in the prior supplement and increase the ATM offering cap by up to $5,228,226 in common stock through WallachBeth Capital. The company has already sold 114,672 shares for ~$1.3M under the existing ATM agreement. With a market cap of only $4M and a recent stock price of $2.91, this additional ATM capacity represents massive potential dilution relative to current market value, and the company has a going concern opinion with persistent net losses.
Key Financial Metrics
Key Facts
- ATM program cap increased by up to $5,228,226 in common stock through WallachBeth Capital
- 114,672 shares already sold for ~$1.3M under the existing ATM agreement since May 2025
- Last reported sale price on October 30, 2026 was $2.91 per share
- Market cap is approximately $4M as of analysis time
- Company has a going concern opinion from its auditor and persistent net losses ($14.9M in 2025)
- The shelf registration (S-3) also includes 1,692,408 shares for resale by Armistice Capital, representing ~282% dilution of the 600,736 shares outstanding post-reverse split
Financial Impact
Up to $5,228,226 in additional ATM capacity, which is ~131% of the current $4M market cap
Risk Factors
- Massive potential dilution from the ATM program relative to the tiny market cap
- Going concern opinion and persistent net losses raise risk of eventual bankruptcy or reverse split
- Armistice Capital's warrant shares (1.69M) create additional overhang and likely aggressive selling
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-049806 |
| Document: 0001493152-26-049806-index-headers.html | 0001493152-26-049806 |
| Document: 0001493152-26-049806-index.html | 0001493152-26-049806 |
| Document: 0001493152-26-049806.txt | 0001493152-26-049806 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 3, 2026 1d ago | 424B5 | $3.04 | awaiting T+60 | awaiting T+60 | $2.93 (+3.60%) |
Nov 2, 2026 2d ago | 424B5 | $3.19 | awaiting T+60 | awaiting T+60 | $2.93 (+8.15%) |
Oct 29, 2026 6d ago | 8-K | $3.03 | awaiting T+60 | awaiting T+60 | $2.93 (−3.30%) |
Oct 23, 2026 12d ago | DEF 14A | $2.83 | awaiting T+60 | awaiting T+60 | $2.93 (+3.53%) |
Oct 15, 2026 20d ago | 8-K | $3.96 | awaiting T+60 | awaiting T+60 | $2.93 (−26.01%) |
Oct 13, 2026 22d ago | 8-K | $3.63 | awaiting T+60 | awaiting T+60 | $2.93 (−19.17%) |
Oct 9, 2026 26d ago | 8-K | $3.90 | awaiting T+60 | awaiting T+60 | $2.93 (+24.87%) |
Oct 9, 2026 26d ago | 424B5 | $4.73 | awaiting T+60 | awaiting T+60 | $2.93 (+37.99%) |
Oct 9, 2026 26d ago | 424B5 | $4.73 | awaiting T+60 | awaiting T+60 | $2.93 (−37.99%) |
Oct 8, 2026 27d ago | 8-K | $5.64 | awaiting T+60 | awaiting T+60 | $2.93 (−48.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers